A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00082854" target="_blank" >RIV/65269705:_____/25:00082854 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.tandfonline.com/doi/abs/10.1080/14796694.2025.2560134" target="_blank" >https://www.tandfonline.com/doi/abs/10.1080/14796694.2025.2560134</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14796694.2025.2560134" target="_blank" >10.1080/14796694.2025.2560134</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

Popis výsledku v původním jazyce

This summary describes results from the CEPHEUS study,which looked at the treatment of adults with a new diagnosisof a type of blood cancer called multiple myeloma thathad not been treated. In addition, adults in this study werenot able to undergo an autologous stem cell transplantfor various reasons, such as older age, health conditions,or social circumstances, and therefore were considered&apos;transplant-ineligible&apos;; or, they did not want to have at ransplant as part of their initial treatment and therefore wereconsidered &apos;transplant-deferred&apos;. Researchers wanted to seeif a dding a treatment called daratumumab (D) to a standardcombination of other medicines known as VRd (whichincludes the medicines bortezomib [V], lenalidomide [R], anddexamethasone [d]) could help reduce the number of multiple myeloma cells found in the participant&apos;s bone marrow and preventthe multiple myeloma from getting worse for a longer period of time compared with getting justVRd. In the CEPHEUS study, half of the participants received D-VRd and the other half received VRd,and all participants stopped bortezomib after 8 treatment cycles.

Název v anglickém jazyce

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

Popis výsledku anglicky

This summary describes results from the CEPHEUS study,which looked at the treatment of adults with a new diagnosisof a type of blood cancer called multiple myeloma thathad not been treated. In addition, adults in this study werenot able to undergo an autologous stem cell transplantfor various reasons, such as older age, health conditions,or social circumstances, and therefore were considered&apos;transplant-ineligible&apos;; or, they did not want to have at ransplant as part of their initial treatment and therefore wereconsidered &apos;transplant-deferred&apos;. Researchers wanted to seeif a dding a treatment called daratumumab (D) to a standardcombination of other medicines known as VRd (whichincludes the medicines bortezomib [V], lenalidomide [R], anddexamethasone [d]) could help reduce the number of multiple myeloma cells found in the participant&apos;s bone marrow and preventthe multiple myeloma from getting worse for a longer period of time compared with getting justVRd. In the CEPHEUS study, half of the participants received D-VRd and the other half received VRd,and all participants stopped bortezomib after 8 treatment cycles.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Future Oncology

ISSN

1479-6694

e-ISSN

1744-8301

Svazek periodika

21

Číslo periodika v rámci svazku

24

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

24

Strana od-do

3115-3138

Kód UT WoS článku

001590326800001

EID výsledku v databázi Scopus

2-s2.0-105018309644